Andrea Lobo,  —

Enrollment is complete in a Phase 2 trial of VG081821, an investigational therapy to treat early to mid-stage Parkinson’s disease, the therapy’s developer, Vimgreen, announced. A total of 150 patients have been randomized to receive a low or high dose of VG081821 or a placebo for 12 weeks, or…

Ryan Reynolds is the face of an educational campaign aiming to raise awareness of lesser-known Parkinson’s disease symptoms: the hallucinations and delusions that can be related to the disease. The ‘More to Parkinson’s’ initiative, sponsored by Acadia Pharmaceuticals, features a six-part series in which the actor…

Sensor-equipped shoes — called NUSHU smart shoes — that are designed to support people with walking difficulties due to Parkinson’s disease and other neurological conditions have received the CE mark of approval in the Europe Union (EU). The shoes perform clinical-grade gait analysis in real time, with biofeedback given…

Photopharmics said the first 100 patients have been enrolled in a Phase 3 trial testing its light-based therapy device, Celeste, to treat Parkinson’s disease. The Light for PD trial, which is expected to enroll 300 patients, is evaluating the device’s safety and efficacy at easing both motor and…

The U.S. Food and Drug Administration (FDA) has approved Medtronic’s Asleep Deep Brain Stimulation (DBS) surgery for people with Parkinson’s disease or essential tremor. “This is a significant advancement in our surgical offering, providing another safe and effective option for patients considering DBS,” Amaza Reitmeier, a vice…

Merck‘s U.S. and Canada life sciences business, MilliporeSigma, signed a memorandum of understanding with Gene Therapy Research Institution (GTRI), a Japanese clinical-stage biotech company, to accelerate the development of a viral vector-based gene therapy for Parkinson’s disease. Under the terms of the non-binding agreement, which symbolizes the parties’…

Nearly one-quarter of deceased athletes with chronic traumatic encephalopathy (CTE), a neurodegenerative disease associated with repetitive head impacts, experienced Parkinson’s disease-like symptoms during their lives, according to a study researchers said is the largest to date exploring the links among contact sports, CTE, and parkinsonism. The researchers found that…

Brenig Therapeutics has raised $65 million to advance its lead candidate, LRRK inhibitor BT-267, into human clinical trials as a possible treatment for idiopathic (of unknown cause) and LRRK2-associated Parkinson’s disease. The funds will be used to test BT-267 in healthy volunteers in a first-in-human study, Brenig said.

The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has awarded a $6 million grant to Lario Therapeutics to advance early studies into CaV2.3 calcium channel inhibitors as a potential disease-modifying therapy for Parkinson’s disease. Lario’s preclinical program is being developed in collaboration with the Oxford…

Scientists have discovered a link between a mutation in the CARS gene and late-onset neurological disorders with symptoms, such as movement disorder, similar to those seen in Parkinson’s disease patients. The mutation, known as CARS E795V, was identified as the cause of a neurological condition affecting nine people…